What is Kadcyla
KADCYLA® is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.
- Kadcyla 100 mg – Single use vial containing powder for concentrate for infusion solution
- Kadcyla 160 mg- single use vial containing powder for concentrate for infusion solution
Storage and handling:
Store vials in a refrigerator at 2°- 8° C until time of reconstitution. Do not freeze or shake
How do we source the Drug?
Globyz Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Company that Manufactures/ Markets:
M/s GENENTECH, A member of the Roche group
Call: +91 07738100125 / +91 07738151650 or